Latest News for Tarsin Mobile Stock (OTC:TMIX)

Tarsin Mobile Inc provides a suite of featured and proven mobile solutions critical to the nature of secure transactions on mobile which include identity confirmation, Geo-Fencing, Geo-Verification, Geo-Location, Geo-Pay, and Geo-Secure. It is also engaged in mobile payments solution and is a regulatory-compliant, secure, end-to-end and agnostic mobile publishing and payment platform. The company is also a real estate development company developing its projects by incorporating state-of-the-art mobile technology in a live work-and-play environment integrating hospitality, retail and themed entertainment.

Tarsin Mobile Inc

<p><i>The companies are collaborating on the development of an uncrewed military vehicle intended for advanced terrain environments and designed without space for a driver</i></p>


News

Textron Systems And Kodiak Collaborates To Develop Autonomous Military Ground Vehicle

WIIM

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Hims & Hers Health shares are trading higher after the company announced the addition of GLP-1 injections to its weight loss portfolio.

<p><i>-- Approval provides U.S. veterans and other U.S. government agency employees who suffer gait and balance impairment due to multiple sclerosis (MS) access to the only portable neurostimulation therapy with the potential to generate neuroplasticity --</i></p>
<p>NEWTOWN, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSDT#NASDAQ">HSDT</a>) ("Helius" or the "Company"), a neurotech company focused on delivering a novel therapeutic neuromodulation approach for balance and gait deficits, today announced the Company's Portable Neuromodulation Stimulator (PoNS&#xAE;) device has been approved for inclusion on Lovell Government Services' ("Lovell") Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage contracts.<br /><br />&nbsp;</p>
<p>The contract award number #V797D-50450 enables the VA and other Federal entities to purchase PoNS at pre-approved pricing via the VA's FSS Medical Equipment and Surgical (Med/Surg) Contract at <a href="https://www.globenewswire.com/Tracker?data=cgnPVgrP0iNcLQC1OVQzKsVd8aNV5H8ZI_BCZpHQHtCCA_SGZDW1Fx67grkfQWMxypnyLWsepqzqHnDHTZS2Q1pmwb3zlcOFDMLhPd480y6Zv2nSzVCft44VwhhyGtPZZixa8uSxYdui8fCTl19TamBRbt-2IlN3amyyhZRdBa2vAz9LrHEbEZlL2DsUqOoQ56uY8Ac2LoXGTMG1v00XA3cWODjr8G407pwNOeLoJxlDClmG0Lfm1KHvXHpDZf3O-hMBQEyXHTwnunt8kr11QCDfT1HZI-v9bUEXLBVPwKhOilJ6sJx-eroTfel5KUGmYu3s0tFHytnBF1V7zvti9pP_7PAbdkz7tkC1HsJfOeST1nBbSfWDD1VGhL7I0ehMUQl867t2ZyalmW3hxj5idMBI3u4Gzi4I2Nlk7Z_A4J7RkvEsKE13bEiq5XKCHKafN_CSRnsAqxM1yJUfdDrMl3qQPDO64ap9a69cGHURSwESjxrnvPBUrqxm9zEuiqOJ">VA National Acquisition Center MedSurg Catalog</a> and via the GSA Advantage online catalog at <a href="https://www.globenewswire.com/Tracker?data=7Db_v2cS7TyUIgicK3R9MWXGrVsjxwST_NpiUzgOPAnmFHgL1pxxqWDRFq3MpqT74vkk3cxvDbopbbETfrcDIET-eVyCDV07YxWInQ2ZEDzv63uqeJLiiYgkJCj_YIGc7dt4Ij5lQ89kpAWtDh6p7iid1eWkDcX3vBnq780_s2TcFyAf9XonmJ65q-IGn5q_SM4dcG3sXHPhuaGIuPabR3yZK5L-0HdY9KMs0C-73_k=">GSA Advantage</a>. The PoNS system, Item # S1-001-02, is priced at $23,843.72 and the PoNS mouthpiece, Item # M1-001 is priced at $7,344.97. PoNS is indicated in the U.S. for use as a short-term treatment of gait deficit in adults with mild-to-moderate symptoms from MS when used in conjunction with physical therapy.</p>
<p>The VA estimates that between 55,000 and 70,000 veterans in the U.S. live with MS.</p>


Contracts

HSDT

Helius Medical Technologies' PoNS Now Available On The VA Federal Supply Schedule And General Services Administration Advantage Contracts; PoNS System, Item # S1-001-02, Priced At $23,843.72 And The PoNS Mouthpiece, Item # M1-001, Priced At $7,344.97

<p>JP Morgan  analyst Samik Chatterjee   maintains Dell Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DELL#NYSE">DELL</a>) with a Overweight and raises the price target from $125 to $155.</p>


Price Target

Analyst Ratings

DELL

JP Morgan Maintains Overweight on Dell Technologies, Raises Price Target to $155

Hims & Hers Health Announces Addition Of GLP-1 Injections To Its Weight Loss Portfolio

Management

GBTC

Grayscale Investments Appoints Peter Mintzberg As Chief Executive Officer Effective August 15, 2024; Succeeds Michael Sonnenshein

<p>Throughout the last three months, 12 analysts have evaluated Sarepta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRPT#NASDAQ">SRPT</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $164.08, a high estimate of $185.00, and a low estimate of $128.00. This current average has increased by 3.76% from the previous average price target of $158.14. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210086_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Sarepta Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Uy Ear</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Buy</td>
<td>$179.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>Hartaj Singh</td>
<td>Oppenheimer</td>
<td>Announces</td>
<td>Outperform</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Anupam Rama</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$175.00</td>
<td>$177.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$128.00</td>
<td>-</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$166.00</td>
<td>-</td>
</tr>
<tr>
<td>Colin Bristow</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$167.00</td>
<td>$164.00</td>
</tr>
<tr>
<td>Kristen Kluska</td>
<td>Cantor Fitzgerald</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$128.00</td>
<td>-</td>
</tr>
<tr>
<td>Brian Abrahams</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$157.00</td>
<td>$151.00</td>
</tr>
<tr>
<td>David Hoang</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$172.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Gena Wang</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$185.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>Gil Blum</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$166.00</td>
<td>$169.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Sarepta Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Sarepta Therapeutics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Sarepta Therapeutics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Sarepta Therapeutics's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/SRPT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Sarepta Therapeutics analyst ratings.</strong></a></p>
<h2>Delving into Sarepta Therapeutics's Background</h2>
<p>Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.</p>
<h3>Breaking Down Sarepta Therapeutics's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Sarepta Therapeutics's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>63.1%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Sarepta Therapeutics's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>8.74%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Sarepta Therapeutics's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>3.97%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>1.11%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>1.44</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


SRPT

12 Analysts Have This To Say About Sarepta Therapeutics

<p>During the last three months, 4 analysts shared their evaluations of Steel Dynamics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STLD#NASDAQ">STLD</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $137.0, along with a high estimate of $160.00 and a low estimate of $118.00. This upward trend is evident, with the current average reflecting a 20.89% increase from the previous average price target of $113.33.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210077_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>A clear picture of Steel Dynamics's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher LeFemina</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Hold</td>
<td>$150.00</td>
<td>-</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Underweight</td>
<td>$118.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>David Gagliano</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$160.00</td>
<td>$130.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Steel Dynamics. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Steel Dynamics compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Steel Dynamics's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Steel Dynamics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/STLD/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Steel Dynamics analyst ratings.</strong></a></p>
<h2>All You Need to Know About Steel Dynamics</h2>
<p>Steel Dynamics Inc operates scrap-based steel minimills with roughly 16 million tons of annual steel production capacity. The company's segment includes steel operations, metals recycling operations, steel fabrication operations, Aluminum Operations Segment, and others. It generates maximum revenue from the steel operations segment.</p>
<h3>Breaking Down Steel Dynamics's Financial Performance</h3>
<p><strong>Market Capitalization:</strong> Boasting an elevated market capitalization, the company surpasses industry averages. This signals substantial size and strong market recognition.</p>
<p><strong>Negative Revenue Trend:</strong> Examining Steel Dynamics's financials over 3 months reveals challenges. As of 31 March, 2024, the company experienced a decline of approximately <strong>-4.07%</strong> in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Steel Dynamics's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>12.44%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>6.51%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Steel Dynamics's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>3.9%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.33</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


STLD

Cracking The Code: Understanding Analyst Reviews For Steel Dynamics

<p>During the last three months, 8 analysts shared their evaluations of Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $21.71, with a high estimate of $27.20 and a low estimate of $16.50. A 2.43% drop is evident in the current average compared to the previous average price target of $22.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210066_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Cleveland-Cliffs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Christopher LeFemina</td>
<td>Jefferies</td>
<td>Announces</td>
<td>Buy</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$19.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Lucas Pipes</td>
<td>B. Riley Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$24.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Bill Peterson</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$23.00</td>
<td>$24.00</td>
</tr>
<tr>
<td>Gordon Johnson</td>
<td>GLJ Research</td>
<td>Announces</td>
<td>Buy</td>
<td>$27.20</td>
<td>-</td>
</tr>
<tr>
<td>Carlos De Alba</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Equal-Weight</td>
<td>$20.00</td>
<td>$20.00</td>
</tr>
<tr>
<td>Alexander Hacking</td>
<td>Citigroup</td>
<td>Announces</td>
<td>Neutral</td>
<td>$22.00</td>
<td>-</td>
</tr>
<tr>
<td>Seth Rosenfeld</td>
<td>Exane BNP Paribas</td>
<td>Announces</td>
<td>Underperform</td>
<td>$16.50</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Cleveland-Cliffs. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Cleveland-Cliffs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Cleveland-Cliffs's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Cleveland-Cliffs's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/CLF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Cleveland-Cliffs analyst ratings.</strong></a></p>
<h2>Get to Know Cleveland-Cliffs Better</h2>
<p>Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.</p>
<h3>Cleveland-Cliffs: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.</p>
<p><strong>Revenue Challenges:</strong> Cleveland-Cliffs's revenue growth over 3 months faced difficulties. As of 31 March, 2024, the company experienced a decline of approximately <strong>-1.81%</strong>. This indicates a decrease in top-line earnings. When compared to others in the Materials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Cleveland-Cliffs's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-1.29%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Cleveland-Cliffs's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-0.89%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Cleveland-Cliffs's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.39%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> With a high debt-to-equity ratio of <strong>0.51</strong>, Cleveland-Cliffs faces challenges in effectively managing its debt levels, indicating potential financial strain.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Evaluating Cleveland-Cliffs: Insights From 8 Financial Analysts

<p>8x8 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EGHT#NASDAQ">EGHT</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Insights from analysts' 12-month price targets are revealed, presenting an average target of $3.5, a high estimate of $4.00, and a low estimate of $3.00. A 20.45% drop is evident in the current average compared to the previous average price target of $4.40. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210045_0.png" alt="price target chart" /></p>
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
<p>The standing of 8x8 among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$3.50</td>
<td>-</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.50</td>
<td>$5.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$3.00</td>
<td>$3.80</td>
</tr>
<tr>
<td>Catharine Trebnick</td>
<td>Rosenblatt</td>
<td>Maintains</td>
<td>Buy</td>
<td>$4.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to 8x8. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of 8x8 compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of 8x8's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into 8x8's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/EGHT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on 8x8 analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind 8x8</h2>
<p>8x8 Inc provides contact-center-as-a-service and unified-communications-as-a-service software applications to approximately 2.5 million users. The company's unified platform enables omnichannel communication to assist employees in communicating across voice, video, text, chat, and contact centers. Geographically, it derives a majority of revenue from the United States.</p>
<h3>8x8: Financial Performance Dissected</h3>
<p><strong>Market Capitalization:</strong> Indicating a reduced size compared to industry averages, the company's market capitalization poses unique challenges.</p>
<p><strong>Decline in Revenue:</strong> Over the 3 months period, 8x8 faced challenges, resulting in a decline of approximately <strong>-0.88%</strong> in revenue growth as of 31 March, 2024. This signifies a reduction in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> 8x8's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-13.15%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> 8x8's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-22.29%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> 8x8's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>-2.98%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>4.68</strong>, caution is advised due to increased financial risk.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


EGHT

Unveiling 4 Analyst Insights On 8x8

<p>In the latest quarter, 6 analysts provided ratings for Planet Labs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>), showcasing a mix of bullish and bearish perspectives.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Planet Labs, presenting an average target of $5.02, a high estimate of $7.00, and a low estimate of $3.90. Marking an increase of 1.41%, the current average surpasses the previous average price target of $4.95. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210035_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Planet Labs. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>-</td>
</tr>
<tr>
<td>Noah Poponak</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.20</td>
<td>$4.80</td>
</tr>
<tr>
<td>Jason Gursky</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$3.90</td>
<td>$4.50</td>
</tr>
<tr>
<td>Josh Sullivan</td>
<td>Benchmark</td>
<td>Lowers</td>
<td>Buy</td>
<td>$4.00</td>
<td>$5.00</td>
</tr>
<tr>
<td>Trevor Walsh</td>
<td>JMP Securities</td>
<td>Lowers</td>
<td>Market Outperform</td>
<td>$4.00</td>
<td>$5.50</td>
</tr>
<tr>
<td>Ryan Koontz</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$7.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Planet Labs. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Planet Labs compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Planet Labs's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Planet Labs's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/PL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Planet Labs analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Discovering Planet Labs: A Closer Look</h2>
<p>Planet Labs PBC is an Earth-imaging company. The company provides daily satellite data that helps businesses, governments, researchers, and journalists understand the physical world and take action.</p>
<h3>Breaking Down Planet Labs's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Planet Labs's revenue growth over a period of 3 months has been noteworthy. As of 31 January, 2024, the company achieved a revenue growth rate of approximately <strong>11.09%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Planet Labs's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>-51.12%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Planet Labs's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of <strong>-5.72%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Planet Labs's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of <strong>-4.25%,</strong> the company may encounter challenges in delivering satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.05</strong>.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Key Takeaways From Planet Labs Analyst Ratings

<p>In the preceding three months, 7 analysts have released ratings for Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $5.89, a high estimate of $6.00, and a low estimate of $5.25. Marking an increase of 12.19%, the current average surpasses the previous average price target of $5.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1716210026_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Taboola.com by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Mark Zgutowicz</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Zach Cummins</td>
<td>B. Riley Securities</td>
<td>Announces</td>
<td>Buy</td>
<td>$5.25</td>
<td>-</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$6.00</td>
<td>-</td>
</tr>
<tr>
<td>Jason Helfstein</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$6.00</td>
<td>$5.50</td>
</tr>
<tr>
<td>Laura Martin</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$6.00</td>
<td>$5.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Taboola.com. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Taboola.com compared to the broader market.</li>
<li><strong>Price Targets:</strong> Delving into movements, analysts provide estimates for the future value of Taboola.com's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Taboola.com's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TBLA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Taboola.com analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Unveiling the Story Behind Taboola.com</h2>
<p>Taboola.com Ltd is a technology company that powers recommendations across the Open Web with an artificial intelligence-based, algorithmic engine. It partners with websites, devices, and mobile apps, collectively referred to as digital properties, to recommend editorial content and advertisements on the Open Web. Geographically it serves Israel, the United Kingdom, Germany, France, Rest of the world whilst it generates the majority of its revenue from the United States.</p>
<h3>Taboola.com: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Taboola.com's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>26.34%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Communication Services sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Taboola.com's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-6.32%</strong> net margin, the company effectively manages costs and achieves strong profitability.</p>
<p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>-2.52%,</strong> the company showcases effective utilization of equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Taboola.com's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>-1.55%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> Taboola.com's debt-to-equity ratio is below the industry average at <strong>0.21</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TBLA

Cracking The Code: Understanding Analyst Reviews For Taboola.com

<p>Homeowners insurance rates in Florida are currently the highest in the nation and are expected to continue rising. Projections from Insurify indicate rates could reach&nbsp;</p>
<p>&nbsp;$11,759 this year.</p>
<p>For seniors on fixed, like Carmen, a 75-year-old Florida West Palm resident battling cancer, the <a href="https://www.benzinga.com/real-estate/24/05/38894475/high-mortgage-rates-drive-down-florida-down-payments-as-sellers-flood-market">financial burden</a> of rising insurance premiums is becoming increasingly difficult to bear.&nbsp;</p>
<p>After receiving another rate increase from Citizens, the state-backed insurance provider, the emotional and financial stress overwhelmed her. "I cried about it. I took a whole day of crying about it," Carmen emotionally shared with Fox 29 News, highlighting that her distress stemmed from her financial situation rather than her health battle.</p>
<p>This latest premium increase was around $300. While that may not seem like much, it's one of many steady insurance increases.</p>
<p>Over the past three years, she has experienced a total increase of $3,000. "I am going to need help or else I have to sell," she explained to her family, a situation that resonates with many seniors on fixed incomes throughout Florida.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li>Warren Buffett once said, "If you don't find a way to make money while you sleep, you will work until you die." <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Here's how you can collect passive rental income without being a landlord</a>.</li>
<li>Elon Musk and Jeff Bezos are bullish on one city that could dethrone New York and become the new financial capital of the US. <a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital">Investing in its booming real estate market has never been more accessible</a>.  </li>
</ul>
<p>Citizens Insurance, often the only option for homeowners like Carmen who face rejection from other insurers due to factors like the age of their roof, the age of the building, or its location, was never intended to be a low-cost option but rather a "last ditch" safety net. Carmen, like many in her situation, finds herself with no other choice.</p>
<p>Insurance agent Robert Norberg, also interviewed by Fox 29, noted, "It's going to happen to everyone: Citizens is going to go up." As Citizens is the insurer of last resort, many homeowners are forced to turn to it despite high costs.</p>
<p>"I work hard to have a home," Carmen said. "Now to maintain a home — it's really getting hard." </p>
<p>Carmen is far from alone in her financial distress. Dera, a resident of Tampa, has found herself in a similar bind, compelled to turn her macramae hobby into a side hustle to afford her rising insurance rates and mortgage payments.</p>
<p><strong>Trending:</strong></p>
<ul>
<li>Become a real estate investor today — <a href="https://www.benzinga.com/money/casa-shares">How to start small by mirroring BlackRock's big move</a>.</li>
</ul>
<p>Dera sells her crafts online and at local farmers markets, stating, "If it&#8217;s a couple of bucks here or there, I appreciate it." Despite her efforts, the fear of losing her home looms large. "The fear is not being able to live in my home anymore because I can&#8217;t afford it because that&#8217;s the absolute fear," she expressed. Her insurance rates have nearly doubled in a year, with her property insurance escalating from $2,460 in 2021 to a quoted $4,550 for the next year, pushing her monthly mortgage payments from $591 to $1,000.</p>
<p>Amid these challenges, there is some hope as the State&#8217;s Office of Insurance Regulator announced that two new companies have been approved to operate in Florida, part of an addition of eight new companies over the last year.</p>
<p>Congressman Byron Donalds and Sen. Rick Scott have introduced the ‘Flood Insurance Relief Act. This <a href="https://www.benzinga.com/real-estate/24/05/38851564/florida-lawmakers-propose-changing-tax-code-to-give-homeowners-insurance-premium-relief">proposed legislation</a> seeks to amend the Internal Revenue Code of 1986 to offer homeowners an "above the line" deduction for insurance premiums, allowing them to deduct these costs from their gross income. This change could lead to substantial savings for many, providing relief from the financial strain experienced by Carmen, Dera and others.&nbsp;</p>
<p>But for now, the reality remains grim for many seniors across Florida. They continue to grapple with the fear that they won&#8217;t be able to keep up as their fixed incomes fail to match the escalating costs of living.&nbsp;</p>
<p><strong>Read Next:</strong></p>
<ul>
<li>Passive income investments are one of the most trusted methods for riding out a recession, so it's no surprise that people are turning to this <a href="https://www.benzinga.com/money/bezos-landlord-100-dollars">Jeff Bezos-backed startup to generate monthly rental income without having to purchase their own property</a>.</li>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/real-estate/23/05/32554601/want-to-grow-your-wealth-passively-these-high-yield-real-estate-notes-might-be-your-holy-grail">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>


Real Estate

'I Cried About It': Elderly Florida Woman Battling Cancer Faces Losing Her Home Due to Soaring Insurance Costs — Seniors Struggle to Keep Up

<p>Iowa Governor<strong> Kim Reynolds</strong> (R) <strong>signed multiple bills into law <strong>Friday</strong> including a measure that seeks to address loopholes in both state and federal hemp laws.</strong> The bill, <a href="https://www.legis.iowa.gov/legislation/BillBook?ga=90&amp;ba=HF2605" target="_blank" rel="noreferrer noopener">House File 2605</a>, imposes <strong>restrictions on hemp-derived consumable products</strong> sold in the state that contain (THC), like Delta-9 drinks and gummies. </p>
<p>Prior to this law, Iowans were able to buy consumable hemp products with less than 0.3% THC by volume, which means that a one-liter drink could have contained up to 1,000 milligrams of THC. Under new law, legal consumable<strong> hemp products can contain up to four milligrams of THC per serving and 10 milligrams per container.</strong> Any hemp products having more than a limited amount will be considered illegal for sale. </p>
<p>"I&nbsp;have concerns about this bill and have heard from individuals and groups on both sides of the issue,"&nbsp;<a target="_blank" href="https://governor.iowa.gov/press-release/2024-05-17/gov-reynolds-signs-final-bills-law" rel="noreferrer noopener">stated Governor</a>&nbsp;Reynolds.&nbsp;"Ultimately, I am signing it into law to protect minors from dangerous and intoxicating products. At&nbsp;the same time,&nbsp;we've&nbsp;taken steps to ensure that children who are resistant to medications and suffer from seizures and other medical conditions continue to have access to consumable hemp alternatives for relief."</p>
<p><em>Changes in cannabis and hemp laws are constantly happening, but the space is definitely growing. To&nbsp;learn all about the future of the cannabis industry, join us at the Benzinga Cannabis Capital Conference this October in Chicago. Hear&nbsp;directly from key industry players and policymakers. Get&nbsp;your tickets now by following&nbsp;<a target="_blank" href="https://www.eventbrite.com/e/benzinga-capital-conference-cannabis-fall-2024-tickets-858948065787?aff=oddtdtcreator" rel="noreferrer noopener">this link</a>.&nbsp;</em></p>
<p>In March,&nbsp;the measure was <a href="https://www.benzinga.com/markets/cannabis/24/03/37654392/iowa-house-passes-bill-capping-thc-in-hemp-products-dem-lawmaker-calls-it-a-mistake">approved&nbsp;in a 79-16 vote</a> with bipartisan support in the state House.&nbsp;</p>
<p>&#8220;I&nbsp;would respectfully ask that we put the safety and well-being of our citizens and our amazing state first in this discussion,&#8221;&nbsp;Rep.&nbsp;<strong>Steven Holt&nbsp;</strong>(R), who managed the&nbsp;bill&nbsp;said at the time.&nbsp;&#8220;First and foremost in this discussion should be the health and well-being of our citizens.&#8221;</p>
<p>Holt added that the lawmakers never planned to legalize intoxicating products when they approved the Iowa Hemp Act.</p>
<p>Stricter regulations in the industry&nbsp;were&nbsp;<a target="_blank" href="https://www.google.com/search?client=firefox-b-d&amp;sca_esv=137e48d954afa8b7&amp;sca_upv=1&amp;q=iowa+cannabis&amp;tbm=nws&amp;source=lnms&amp;prmd=nisvmbtz&amp;sa=X&amp;ved=2ahUKEwjB15Le9puGAxUhg_0HHfL2DhMQ0pQJegQIEhAB&amp;biw=1280&amp;bih=595&amp;dpr=1.5" rel="noreferrer noopener">not welcomed</a>&nbsp;by retailers and brewers that sell products with THC.&nbsp;</p>
<p><em>See Also:&nbsp;<a href="https://www.benzinga.com/markets/cannabis/24/03/37896144/washington-state-gov-signs-bill-eliminating-medical-marijuana-tax-iowa-to-add-25-excise-tax-on-h" target="_blank" rel="noreferrer noopener">Iowa Senate Committee Approves Bill Adding 25% Excise Tex On Consumable Hemp&nbsp;Products</a></em></p>
<p><em>Photo: Benzinga edit with images by&nbsp;<a href="https://www.flickr.com/people/22007612@N05" target="_blank" rel="noreferrer noopener">Gage Skidmore</a>&nbsp;&nbsp;via Wikimedia Commons and Roxana<a href="https://www.shutterstock.com/g/rgbspace" target="_blank" rel="noreferrer noopener">&nbsp;Gonzalez via</a>&nbsp;Shutterstock</em></p>


Cannabis

Iowa GOP Governor Signs Bill Limiting THC Content In Hemp-Derived Consumable Products

<p><strong>Wix.com Ltd&nbsp;</strong>(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) reported its&nbsp;fiscal first-quarter 2024 results.&nbsp;Revenue grew 12%&nbsp;Y/Y&nbsp;to $419.8 million, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/05/n38911580/wix-reports-first-quarter-2024-results" rel="noreferrer noopener">analyst consensus estimate of $417.8 million</a>.&nbsp;</p>
<p>Adjusted EPS of $1.29 beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of $1.03</a>. The&nbsp;stock gained after the results.</p>
<p>Partners revenue&nbsp;in the&nbsp;first quarter&nbsp;of 2024 was&nbsp;$138.4 million, up&nbsp;33%&nbsp;y/y.</p>
<p><strong>Segments:</strong>&nbsp;Creative Subscription revenue increased 9%&nbsp;Y/Y&nbsp;to $304.3 million.&nbsp;The Creative Subscriptions bookings&nbsp;climbed 7%&nbsp;Y/Y&nbsp;to $334.6 million<strong>.&nbsp;</strong>Creative Subscriptions ARR was $1.24 billion, up 10%&nbsp;Y/Y.</p>
<p>Business&nbsp;Solutions&#8217;&nbsp;revenue rose 20%&nbsp;Y/Y&nbsp;to $115.5 million, and&nbsp;the&nbsp;bookings jumped 21%&nbsp;Y/Y&nbsp;to $122.6 million.&nbsp;</p>
<p>The adjusted gross margin expanded to 68% from 67% a year ago. Wix.com generated $113.8 million in operating cash flow and held $883.5 million in cash and cash equivalents as of March-end.</p>
<p>Avishai Abrahami, Wix Co-founder and CEO said,&nbsp;&#8220;This outperformance was underpinned by robust business fundamentals as well as strong product traction, particularly for our expansive AI product offering and Wix Studio. Notably, we saw extremely strong usage of our AI Website Builder&nbsp;that&nbsp;was launched earlier in the quarter with hundreds of thousands of sites already created using the tool over just a few months.&nbsp;Wix Studio&nbsp;also&nbsp;continues to perform ahead of plan, with over one million Studio accounts created since our August launch.&#8221;</p>
<p><strong>Outlook:</strong>&nbsp;Wix.com expects fiscal second-quarter revenue of $431&nbsp;million &#8211;&nbsp;$435 million versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">consensus of $435.21 million</a>.</p>
<p>Wix.com expects fiscal 2024 revenue of $1.738 billion&nbsp;&#8211;&nbsp;$1.761 billion (prior $1.726 billion-$1.757 billion) vs. the consensus of $1.75 billion. Wix.com projects 2024 bookings of $1.796&nbsp;billion &#8211;&nbsp;$1.826 billion<strong>&nbsp;</strong>(prior $1.784 billion – $1.813 billion).</p>
<p>The company expects to generate free cash flow, excluding headquarters costs, of $445&nbsp;million &#8211;&nbsp;$455 million (prior<strong>&nbsp;</strong>$370 million – $400 million.</p>
<p><strong>Price Action</strong>: WIX shares are up 9.82% at $149.00 premarket&nbsp;at the last check Monday.</p>


Earnings

Equities

Guidance

Movers

Website Creator Wix Gains After Q1 Print, What's Going On?

Macro Economic Events

Economics

Federal Reserve

Fed Vice Chair Barr Says Regulators Considering Restriction On How Much Banks Can Rely On 'held-to-maturity' Securities Under Liquidity Requirements; Regulators Reviewing Regulatory Treatment Of Certain Types Of Deposits, Including Ones Tied To Venture Capital Or Cryptocurrency Businesses

Fed Vice Chair Barr Says Regulators Exploring 'Targeted Adjustments' To Existing Liquidity Rules;  Regulators Considering Requiring Larger Banks To Hold Minimum Levels Of Reserves And Pre-positioned Collateral At Discount Window; Larger Banks Would Be Required To Have Available Liquidity To Cover Uninsured Deposits

Fed Vice Chair Barr Says Q1 Inflation "Disappointing," Did Not Provide The Confidence Needed To Ease Monetary Policy; Fed Will Need To Allow Tight Policy "further Time To Continue To Do Its Work"; Fed In A Good Position To "hold Steady" And Watch Economy; Vigilant To The Risks To Both Inflation And Employment Mandates; Current Approach "prudent" To Manage Both Sets Of Risks

<p>Benchmark  analyst Bill Sutherland   maintains Quipt Home Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QIPT#NASDAQ">QIPT</a>) with a Buy and lowers the price target from $10 to $9.</p>


QIPT

Benchmark Maintains Buy on Quipt Home Medical, Lowers Price Target to $9

<p>Jefferies  analyst Brent Thill   maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $150 to $160.</p>
